Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Memantin

Klassificering: A

Preparat: Axura, Ebixa, Ebixa®, Marbodin, Memantin Ebb, Memantin Orion, Memantin STADA, Memantine Accord, Memantine LEK, Memantine Mylan, Memantine ratiopharm, Memantine Sandoz, Memantine-Merz, Mentixa, Nemdatine

ATC kod: N06DX01

Substanser: memantin, memantinhydroklorid

Sammanfattning

Inga studier har påvisat skillnader i effekt mellan könen vid memantinbehandling.
 
Kunskapsunderlaget avseende skillnader mellan kvinnor och män är begränsat och motiverar inte olika dosering eller behandling.

Additional information

Pharmacokinetics and dosing

Following a multiple dose administration of memantine 20 mg twice a day, Cmax and AUC were approximately 45% higher in women than in men. However, there were no differences in Cmax or AUC when body weight was taken into account [1]. In a pharmacokinetic study (34 men, 74 women), men had higher oral clearance (CL/F) [4]. Despite the pharmacokinetic differences of memantine, the clinical studies have shown effect with similar doses in men and women, and no sex differentiation in dosing has been suggested [5].

Effects

Other information

An American retrospective data analysis investigated the relationship between adherence to oral AD therapy (rivastigmine, donepezil, galantamine or memantine) and other variables. Male AD patients were approximately 18% more likely to be adherent to index oral AD therapy than female patients [7].In a retrospective analysis of effect of memantine with or without vitamin E (15 men, 28 women), no differences between men and women were shown [6].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of memantine have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande memantin (ATC-kod N06DX01) på recept i Sverige år 2015, totalt 12 973 kvinnor och 8 756 män. Det motsvarar 2,7 respektive 1,8 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 80 år och äldre hos båda könen. I genomsnitt var läkemedel innehållande memantin 1,6 gånger vanligare hos kvinnor [7].

Uppdaterat: 2019-02-26

Litteratursökningsdatum: 2013-05-14

Referenser

  1. Namenda (memantine). DailyMed [www]. US National Library of Medicine. [updated 2013-01-01, cited 2013-05-14]. länk
  2. Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010;26:1957-65. PubMed
  3. Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet. 2013;52:211-23. PubMed
  4. Memantine. Summary of Product Characteristics. European Medicines Agency; 2013.
  5. Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol. 2012;25:121-7. PubMed
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-30.] länk

Författare: Linnéa Karlsson Lind, Desirée Loikas

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson